Viatris: The Market Is Still Pricing a Company That No Longer Exists (NASDAQ: VTRS)

Viatris generates $2.2 billion in annual free cash flow against an $18.5 billion market capitalization—an 11.9% free cash flow yield. Yet the market continues to value the company as though it were still the debt-laden post-merger business of 2021. That company no longer exists.

THE ONE NUMBER THAT FRAMES THE THESIS

Readers of this newsletter will recognize the setup. We look for companies where the market is anchored to an outdated narrative while the financial reality has already changed. Viatris fits that pattern.

The business generates approximately $2.2 billion in annual free cash flow—roughly $1.90 per diluted share—yet trades at just $16 per share, an 11.9% FCF yield. That discount reflects how investors viewed Viatris in 2021: a highly leveraged post-merger generics company with no clear capital return story. Today, leverage is at target, a $650 million cost savings program is underway, buybacks are accelerating, and two pipeline catalysts provide additional upside without being central to the investment case.

The thesis is straightforward: investors are paying a 12% FCF yield for a business that has largely completed its balance-sheet repair and is entering a phase where that cash flow can increasingly be returned to shareholders. The market is still pricing the past, creating the opportunity today.

THE BUSINESS — WHAT VIATRIS ACTUALLY IS IN 2026

Viatris was created in November 2020 through the merger of Mylan and Pfizer's Upjohn division. The combination brought together a global generics platform and a portfolio of established brands such as Lipitor, Viagra and Norvasc. It also left the company with approximately $20 billion of debt, declining generic revenues and a complex integration that weighed heavily on investor sentiment.

The market's skepticism appeared justified. For the next three years, the stock steadily declined as revenue eroded, leverage remained elevated and management focused almost entirely on repairing the balance sheet rather than returning capital to shareholders.

What the market failed to appreciate was the transformation already underway. Between 2021 and 2025, Viatris divested several non-core businesses, generating roughly $6.9 billion of proceeds that were largely directed toward debt reduction. By early 2026, total debt had fallen to $12.5 billion and leverage had reached 2.9x EBITDA—comfortably within management's target range.

The balance-sheet repair is largely complete. The market, however, continues to value Viatris as though it were still in the middle of that turnaround. That disconnect is the investment opportunity.

THE FCF BRIDGE — WHAT YOU ARE ACTUALLY BUYING AT $16

The table below walks from guided 2026 adjusted EBITDA to free cash flow available for capital deployment. All figures use the guidance midpoint unless noted.

The share count compression is material. At today's valuation, every dollar spent on share repurchases is effectively purchasing an asset producing an 11–12% free cash flow yield. If buybacks continue at the current pace, an investor owning 100 shares today could own the economic equivalent of roughly 108–109 shares of the business a year from now without investing another dollar. That is the power of retiring shares when a company trades materially below intrinsic value.

At a $16 share price and $18.5 billion market cap, the reported FCF yield is approximately 11.6%. On an ex-restructuring basis — the cleanest measure of ongoing earnings power — the yield approaches 16%. The $2.5 billion in total cash available for deployment guided for 2026 includes proceeds from minor asset sales alongside operating FCF, which accounts for the difference versus the FCF line.

The $650 million cost savings program adds a second layer. Net of $250 million reinvestment into the business, the program contributes approximately $400 million of net cost reduction over three years — roughly $133 million per annum in incremental FCF by 2028. That is not in current guidance.

WHY THE NEXT 12 MONTHS ARE DIFFERENT

The market already knows Viatris generates substantial free cash flow. What it has yet to fully price is how that cash flow is about to be deployed.

The company has completed the most difficult phase of its turnaround. Leverage has reached management's target range, removing debt reduction as the overwhelming capital allocation priority. That allows free cash flow to shift increasingly toward share repurchases, where buying stock at an 11–12% FCF yield is highly accretive to remaining shareholders.

At the same time, the $650 million cost savings programme begins contributing meaningfully over the next several years, while two FDA decisions in the second half of 2026 provide potential upside that is not required for the investment thesis.

In other words, the next year should look fundamentally different from the last five. Instead of repairing the balance sheet, Viatris is entering the phase where shareholders begin to participate directly in the cash generation of the business.

THE DEBT — STILL LARGE, BUT THE TRAJECTORY IS CONFIRMED

The honest version of the bear case starts here. $12.5 billion is still a substantial debt load — roughly 0.68x the current market cap. Annual interest expense is approximately $515 million, which is a real drag on FCF. The leverage story is not finished.

What has changed is that the leverage story is no longer uncertain. At 2.9x EBITDA, Viatris is inside its own target range. The debt is 91% fixed-rate, limiting refinancing risk. Moody's rates it Baa3 (stable); Fitch rates it BBB (stable) — investment grade on both. The company addressed its most pressing maturity last week, issuing €650 million of 4.25% senior notes due 2033 to refinance the $1.675 billion 3.95% 2026 notes at maturity. The next meaningful maturity wall is the $1.9 billion coming due over the subsequent two years — manageable at the current FCF run rate.

THE PIPELINE — FREE OPTION VALUE, NOT THE THESIS

This section exists to frame what the pipeline is and is not. The CCF thesis on VTRS does not require a single pipeline approval. It is built entirely on the FCF yield, the debt trajectory, and the buyback compounding. Pipeline is option value — if it lands, the stock re-rates materially; if it misses, the core thesis is unchanged.

With that framing, two events sit on the 2026 calendar.

Xulane LO (PDUFA: 30 July 2026). A low-dose estradiol contraceptive patch — a supplemental NDA seeking approval for a reformulated version of an existing Viatris product. Management described strong engagement at the ACOG annual meeting in May. Market is sizable, approval would likely come with limited generic competition near-term.

MR-141 / Phentolamine ophthalmic solution for presbyopia (PDUFA: 17 October 2026). Presbyopia — age-related near-vision loss — affects roughly 1.8 billion people globally and is currently managed almost entirely by reading glasses. A once-daily eye drop with efficacy data already presented at multiple congresses would enter a market with minimal pharmaceutical competition. Phase III data has been presented. The sNDA is under review. Barclays recently raised its price target to $22 citing this catalyst specifically.

Neither outcome changes the price we are willing to pay today. Both represent genuine upside that is not reflected in the current $16 share price.

FCF SENSITIVITY TABLE

The table below models FCF available for deployment at three revenue scenarios: bear (flat revenue, no cost savings contribution), base (guidance midpoint, partial cost savings benefit by 2027), and bull (guidance top end, full cost savings ramp, presbyopia approval). All figures in billions.

Shares outstanding assumed at 1.16B (bear), 1.10B (base), 1.05B (bull) reflecting buyback execution. Dividend held constant at $0.48 across scenarios.

Even in the bear case — flat revenue, no cost savings, no pipeline approval — the FCF yield at $16 remains above 9%. That is the downside case for a business generating $1.7 billion in annual free cash flow. It is not a value trap.

THE HONEST RISKS

Debt in absolute terms. $12.5 billion is still $12.5 billion. At 2.9x EBITDA leverage sits at target, but any EBITDA compression — from a significant generic pricing shock, a major market loss, or an operational disruption — would push leverage back above the 3.2x ceiling and likely constrain capital return.

India manufacturing compliance. Viatris operates a significant portion of its manufacturing out of India. The Indore facility warning letter (now remediated) and the fire at the Nashik facility in early 2026 are reminders that operational risk in pharmaceutical manufacturing is real. A new warning letter or import alert on a major facility could disrupt supply, impair revenues, and hit FCF.

GAAP earnings are negative. The reported GAAP EPS is -$0.26 — the legacy of $2.9 billion in goodwill impairments taken during restructuring. Passive screeners and dividend investors scanning on GAAP multiples will never buy VTRS. That institutional exclusion is part of why the yield persists, but it is also a genuine framing risk for any investor who anchors to GAAP.

Generic pricing erosion is structural. North America generic drug prices deflate approximately 8–12% annually in competitive categories. Viatris partially offsets this with new launches and established brand stability, but the headwind is permanent and does not disappear as the balance sheet improves.

Pipeline binary outcomes. Both the July and October PDUFA dates are yes/no events. A rejection on MR-141 in particular — given how much sell-side attention it has received — could knock 10–15% off the stock in a session. The thesis survives; the entry point may improve.

WHAT COULD CAUSE THE STOCK TO RERATE

It likely won't be a single earnings report. Instead, the combination of sustained buybacks, a declining share count, continued execution on the cost-savings program, and stable leverage should steadily increase free cash flow per share. Over time, that makes it increasingly difficult for the market to continue valuing Viatris as a company still in turnaround mode.

THE BOTTOM LINE

The market still values Viatris as a turnaround story. In reality, much of the balance sheet turnaround is already complete. Balance-sheet repair has largely given way to capital returns, while buybacks executed at an 11–12% free cash flow yield should steadily increase per-share value. Investors are not paying for pipeline success. They are buying a business generating a double-digit free cash flow yield while management retires shares at an attractive valuation.

At $16 per share, Viatris trades at an 11.9% free cash flow yield and pays a modest 3% dividend, leaving the majority of its excess cash available for buybacks and continued balance-sheet improvement. Over the next 12 months, the share count is likely to decline, the cost savings program should begin flowing through to free cash flow, and two FDA decisions provide additional upside without being essential to the investment case.

Whether the market recognizes this transformation over the next quarter or the next two years is impossible to predict. What matters is that today's valuation still reflects the company Viatris was in 2021, not the business it has become. For long-term investors, buying a company generating an 11–12% free cash flow yield while management compounds per-share value through disciplined capital allocation has historically been an attractive place to start.

DISCLAIMER: This newsletter is for informational and educational purposes only. Nothing published here constitutes personalized financial or investment advice. All investments carry risk including the possible loss of principal. The author holds a position in VTRS. Do your own research and consult a qualified financial adviser before making any investment decision.